Loading
Total declarations
Companies
▲ Purchases (18 ops.)
▼ Sales (3 ops.)
Latest filing published 05 Oct 2026 for Altimmune, Inc..
Filing timeline
BuySaleGregory L. Weaver
Insider track record
Disclosed buys
18
Disclosed sells
3
Signal history
Closed purchases
Market purchases
5
Positive at T+90
20%
Median T+90
-11.3%
Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -20.1%Entry US$3.34 · Close 05 Oct 2026 US$2.67
- -29.3%Entry US$3.86 · Close at T+90 US$2.73
- -39.4%Entry US$5.97 · Close at T+365 US$3.62
- +22.7%Entry 16.50 · Close at T+365 20.25
- -79.8%Entry US$18.03 · Close at T+365 US$3.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Gregory L. Weaver: trading record in brief
Gregory L. Weaver is a declared insider at 8 companies (finance chief); the most frequent names are Atossa Therapeutics, Inc., Altimmune, Inc. and Eloxx Pharmaceuticals, Inc. Between 25 May 2006 and 1 October 2026, the trades on record add up to 41 filings.
The open-market side counts 18 purchases for €411k alongside 3 sales for €567k. Sales outweigh purchases by €156k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 8 share grants and 10 option exercises. Since January 2026: 2 purchases and no sales on the market.
The median purchase comes to €18k. 4 out of 6 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 5 purchases show a median change of -11.3%, with the price up in 20% of them. Past outcomes like these are no guarantee of what comes next.
On 5 October 2026 came the latest disclosure, a share grant for €11k in Altimmune, Inc. The last insider purchase was made public on 1 April 2026, 206 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Gregory L. Weaver
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations11 total
14,475 shares0Common Stock, par value $0.0001SEC:0001251779-26-000011:0
4,379 shares@ US$2.76Common Stock, par value $0.0001SEC:0001251779-26-000011:1
1,753 shares@ US$2.4140.0007% mcap3.9% of flowCommon Stock, par value $0.0001SEC:0001251779-26-000009:0
10,000 shares@ US$3.149929.0% of flowCommon Stock, par value $0.0001SEC:0001251779-26-000007:0
Canonical exit: 30 Jun 2026 (T+90)
5,000 shares@ US$3.5416.2% of flowCommon Stock, par value $0.0001SEC:0001251779-26-000005:0
Canonical exit: 4 Jun 2026 (T+90)
18,750 shares0Common Stock, par value $0.0001SEC:0001251779-25-000006:0
10,000 shares@ US$5.199650.9% of flowCommon Stock, par value $0.0001SEC:0001104659-25-023724:0
Canonical exit: 11 Jun 2025 (T+90)
50,000 shares@ US$0.6531.1% of flowCommon StockSEC:0001437749-23-032461:0
50,000 shares@ US$0.9746.2% of flowCommon StockSEC:0001437749-23-017896:0
Canonical exit: 18 Sept 2023 (T+90)
4,581 shares@ US$5.6422.7% of flowCommon StockSEC:0001437749-21-016573:0
4,666 shares@ US$15.00100.0% of flowCommon SharesSEC:0000899243-21-025732:0
Canonical exit: 20 Sept 2021 (T+90)
11 of 11 declarations
